Video
According to Christoph Lacroix (ETH Zurich), bifidobacteria are critical in the development of the neonatal microbiota. Here's why.
Savita Bernal, Chief Business Officer at MaaT Pharma, discussed the Phase 3 trial (ARES) in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement.
Christine Moissl-Eichinger (Medical University of Graz, Austria) explains the changes in the microbiome of astronauts.
Fabio Grassi, Founder at MV BioTherapeutics SA, discussed how to understand the mechanisms of action for microbiome contributions to cancer therapeutic response in patients.
Felix Faupel, Chief Commercial Officer at Bacthera, discussed how the combination of the new Lonza Capsugel® Enprotect™ capsule and Bacthera services will accelerate time-to-human and time-to-market.
Gynecologist Franco Vicariotto and Virginia Franco, CEO and Co-Founder Yoni Solutions, discuss how personalized analysis and personalized therapy are within the reach of today's woman.
Biopharma companies are currently developing Live Biotherapeutic Products. We discussed this topic with Morten Isaksen (BIO-ME).
Emily Hollister discussed how Diversigen demonstrates the rapidity of microbial gene expression changes potentially impacting host-microbiome interactions.
Benjamin Hadida discusses how to validate innovative clinical trial design and overcome challenges of robust-large scale manufacturing.
Yvonne Nyavor discusses the improvement of analysis methods for Live Biotherapeutics Products.
